• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet posts Street-beating Q4 with Omnipod revenues up nearly 20% from 2020

February 23, 2022 By Sean Whooley

Insulet Omnipod 5 Dexcom G6
Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]
Insulet (NSDQ:PODD) this evening reported fourth-quarter results that came in ahead of the Wall Street consensus forecast amid strong sales growth.

The Acton, Massachusetts–based maker of Omnipod insulin delivery systems posted profits of $29.2 million, or 42¢ per share, on sales of $307.7 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain from losses of $17.1 million the year prior on sales growth of 25%.

Insulet’s earnings per share of 42¢ came in 10¢ ahead of projections on Wall Street, where analysts were looking for sales of $301.1 million.

The company brought in $275.8 million in revenues for its Omnipod insulin delivery platform for the quarter, representing a 19.3% increase. Insulet just last month received FDA clearance for the next-generation Omnipod 5 and is amid a limited launch of the platform.

“2021 was another successful year for Insulet, as we reached an important milestone of over $1 billion in revenue and advanced our strategic priorities,” Insulet President and CEO Shacey Petrovic said in a news release. “We entered 2022 with significant momentum and expect continued strong growth. We are incredibly excited about the commercial launch of Omnipod 5, which is a transformative technology offering users award-winning innovation, improved outcomes and quality of life. Our commitment to improving the lives of people with diabetes has never been stronger.”

Insulet projects revenue growth to range between 12% and 16% for the full year 2020, with an increase of between 15% and 20% expected for Omnipod platform sales.

PODD shares were down 3.8% at $222 per share after the market closed today.

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS